Skip to content
Article Rich – Lifestyle
Author:
Andelyn Biosciences
Andelyn Biosciences to Develop and Manufacture AAV Gene Therapy for Celliaz to Treat Retinitis Pigmentosa
November 12, 2026
/C O R R E C T I O N — Andelyn Biosciences/
September 18, 2026
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx’s FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIIA)
September 18, 2026
Andelyn Biosciences to Scale Manufacturing for Genprex’s Diabetes Gene Therapy Program
September 1, 2026
Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen’s University to Treat GM2 Gangliosidoses
August 18, 2026